Researchers have quantified the progression of the most common spinocerebellar ataxias (SCAs) over a follow-up period of up to 8 years in steps to improve sample size calculations for future ...
A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings. A key opinion ...
While costly, Skyclarys has been found to slow the progression of Friedreich's ataxia, which progressively damages the ...
Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia ...
AJMC ®: What is your background in treating Friedreich ataxia (FA) in clinical practice and in clinical trials? KUO: I am the director of Columbia University’s ataxia center and have extensive ...
AOIFE Gavan was just 11 when climbing stairs and walking started to become difficult — two years later, she was told she had ...
The approval of SKYCLARYS reflects Biogen's commitment to pioneering innovation in rare diseases, driving progress in patient care, and addressing critical unmet needs Before SKYCLARYS, individuals ...
Friedreich’s ataxia is a genetic condition that affects the nervous system. It’s caused by a change in a gene responsible for regulating energy production within cells. This change means that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results